Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2022 · 10-Q
Revenue$4.50M$4.50M+36.8% vs Q2 2021 Net Income-$5.76M-$5.76MN/M vs Q2 2021 EPS Diluted-$0.16-$0.16N/M vs Q2 2021 Gross Profit$1,349,665+49.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,431,965N/M Free Cash Flowderived-$2,431,965— Margins · derivedGross margin30.0%+2.5 pt vs Q2 2021
Operating margin-129.6%+74.5 pt vs Q2 2021
Net margin-128.0%+71.5 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end